Dr. Falk Pharma Announces Positive Results From Phase 3 Trial on Norucholic Acid
Berlin: Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid (NCA) in primary sclerosing cholangitis (PSC). According to BERNAMA News Agency, the